Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now

FIVE at FIVE AU: ASX up as gold rallies

Published 04/04/2024, 04:05 pm
Updated 04/04/2024, 04:30 pm
© Reuters FIVE at FIVE AU: ASX up as gold rallies

The ASX 200 ended 0.42% higher to 7,815 today led by the interest rate-sensitive Tech and Real Estate sectors. All sectors ended the day higher.

Small caps had a strong day, with the ASX Small Ordinaries up 1.08%, as was the ASX All Ordinaries Gold index (+1.12%).

Gold stocks rallied after the gold price reached a new record high of US$2,300 and the precious metal is now up by more than 4.3% over the past five days as investors look to protect themselves against stubbornly high inflation and the risk of escalating conflict in the Middle East.

The new high also followed comments from Federal Reserve chair Jerome Powell overnight that the latest inflation data did not “materially change” things. The comments also led to traders increasing their rate-cut expectations.

Powell warned that the Fed was “not yet done” taming inflation, and the Fed needed “greater confidence” that price pressures were easing before it cut interest rates.

Some of the best performers in the Materials sector today were South32, up 4.62%, Lynas Rare Earths, up 3.36%, and IGO Ltd added 2.67%.

Five at five

Astral Resources hits up to 45.6 g/t gold as new results extend strike at Kamperman

Recent reverse circulation (RC) drilling by Astral Resources NL (ASX:AAR) at Kamperman prospect of the Feysville Gold Project south of Kalgoorlie in Western Australia, has successfully in-filled the prospect to the south and extended the known mineralised strike by a further 100 metres to the north.

Read more

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Noxopharm and UniSA receive Tour de Cure grant for brain cancer research

Noxopharm Ltd (ASX:NOX, OTC:NOXOF) and the University of South Australia (UniSA) have received A$100,000 from Tour de Cure to progress their encouraging preclinical work on a novel first-in-class brain cancer drug.

Read more

Imugene granted China patent for Oncolytic Virotherapy CF33

Imugene Ltd (ASX:IMU, OTC:IUGNF) has gained access to the largest pharmaceutical market in Asia with the grant of a patent for its Oncolytic Virotherapy CF33 from the Chinese Patent Office, following earlier grants in Japan and South Korea.

Read more

Ora Banda Mining progresses Riverina and Sand King underground gold mines

Ora Banda Mining Ltd (ASX:OBM) continues to advance its 'DRIVE to 100' campaign targeting production of more than 100,000 ounces of gold from the Davyhurst Project in Western Australia in FY2025.

Read more

Torque Metals kicks off 6,500-metre drilling campaign at Paris Gold Project

Torque Metals Ltd (ASX:TOR) has kicked off a 6,500-metre reverse circulation (RC) and diamond drilling campaign at the Paris Gold Project near Kalgoorlie at the heart of Western Australia’s Goldfields in a bid to extend high-grade structures.

Read more

On your six

Can Nike maintain its grip on sneaker supremacy?

Despite surpassing Wall Street's expectations for third-quarter revenue and profits — largely thanks to holiday sales and price changes in North America — questions linger over Nike Inc (NYSE:NYSE:NKE, ETR:NKE)'s future, writes Stake market analyst Megan Stals.

Read more

One to Watch

Antipa Minerals delivers significant exploration achievements

Antipa Minerals Ltd (ASX:AZY) managing director Roger Mason sits down with Proactive’s Jonathan Jackson to discuss the latest developments at the company’s 100%-owned Minyari Dome Project and the company's strategic partnerships.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Watch more

Read more on Proactive Investors AU

Disclaimer

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.